Ironwood Pharmaceuticals Quarterly Balance Sheets Chart
Quarterly
|
Annual
Ironwood Pharmaceuticals Quarterly Balance Sheets Table
Quarterly
|
Annual
| Unit: USD | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 | 2023-03-31 | 2022-12-31 | 2022-09-30 | 2022-06-30 | 2022-03-31 | 2021-12-31 | 2021-09-30 | 2021-06-30 | 2021-03-31 | 2020-12-31 | 2020-09-30 | 2020-06-30 | 2020-03-31 | 2019-12-31 | 2019-09-30 | 2019-06-30 | 2019-03-31 | 2018-12-31 | 2018-09-30 | 2018-06-30 | 2018-03-31 | 2017-12-31 | 2017-09-30 | 2017-06-30 | 2017-03-31 | 2016-12-31 | 2016-09-30 | 2016-06-30 | 2016-03-31 | 2015-09-30 | 2015-06-30 | 2015-03-31 | 2014-06-30 | 2014-03-31 | 2013-06-30 | 2013-03-31 | 2012-09-30 | 2012-06-30 | 2012-03-31 | 2011-09-30 | 2011-06-30 | 2011-03-31 | 2010-09-30 | 2010-06-30 | 2010-03-31 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| assets | ||||||||||||||||||||||||||||||||||||||||||||||||||||||
| current assets: | ||||||||||||||||||||||||||||||||||||||||||||||||||||||
| cash and cash equivalents | 92,852,000 | 108,481,000 | 88,559,000 | 88,211,000 | 105,524,000 | 121,540,000 | 92,154,000 | 110,164,000 | 175,321,000 | 740,342,000 | 656,203,000 | 574,188,000 | 504,365,000 | 593,371,000 | 620,129,000 | 574,276,000 | 492,699,000 | 438,469,000 | 362,564,000 | 307,555,000 | 253,252,000 | 231,143,000 | 177,023,000 | 139,231,000 | 98,908,000 | 119,045,000 | 173,172,000 | 141,562,000 | 145,415,000 | 144,788,000 | 162,640,000 | 182,132,000 | 133,319,000 | 182,937,000 | 277,332,000 | 280,926,000 | 248,077,000 | 256,450,000 | 63,692,000 | 95,357,000 | 205,129,000 | 219,461,000 | 105,302,000 | 125,867,000 | 87,083,000 | 131,612,000 | 68,820,000 | 48,185,000 | 46,214,000 | 58,696,000 | 35,384,000 | 76,338,000 | ||
| accounts receivable | 86,172,000 | 39,768,000 | 81,886,000 | 76,202,000 | 58,108,000 | 72,015,000 | 129,122,000 | 124,546,000 | 118,990,000 | 115,749,000 | 115,458,000 | 116,545,000 | 102,357,000 | 105,515,000 | 114,042,000 | 101,773,000 | 102,252,000 | 87,152,000 | 122,351,000 | 113,250,000 | 105,379,000 | 17,703,000 | 11,279,000 | 2,017,000 | 22,604,000 | 3,291,000 | 20,991,000 | 10,193,000 | 6,748,000 | 4,988,000 | 4,280,000 | 3,975,000 | 1,152,000 | 1,174,000 | 1,272,000 | 908,000 | 2,570,000 | 1,057,000 | 862,000 | 13,000 | 12,000 | 169,000 | 22,000 | 109,000 | 74,000 | 110,000 | 207,000 | 372,000 | 196,000 | 192,000 | ||||
| prepaid expenses and other current assets | 12,729,000 | 12,330,000 | 11,923,000 | 14,191,000 | 14,548,000 | 14,619,000 | 12,012,000 | 18,112,000 | 22,500,000 | 9,033,000 | 7,715,000 | 7,011,000 | 9,854,000 | 8,537,000 | 8,689,000 | 10,221,000 | 12,320,000 | 10,890,000 | 9,189,000 | 10,777,000 | 14,394,000 | 10,443,000 | 10,685,000 | 11,863,000 | 8,880,000 | 8,327,000 | 11,063,000 | 21,699,000 | 16,678,000 | 8,924,000 | 8,074,000 | 8,235,000 | 8,664,000 | 9,216,000 | 7,622,000 | 7,731,000 | 6,502,000 | 6,595,000 | 9,212,000 | 6,338,000 | 5,286,000 | 9,565,000 | 13,853,000 | 7,877,000 | 5,964,000 | 4,048,000 | ||||||||
| total current assets | 191,753,000 | 160,579,000 | 182,368,000 | 178,604,000 | 178,180,000 | 208,174,000 | 233,288,000 | 253,610,000 | 317,599,000 | 866,374,000 | 780,626,000 | 698,994,000 | 617,826,000 | 710,101,000 | 745,225,000 | 695,374,000 | 620,268,000 | 538,246,000 | 495,839,000 | 433,317,000 | 374,275,000 | 333,943,000 | 306,852,000 | 257,638,000 | 220,985,000 | 201,832,000 | 266,435,000 | 248,548,000 | 279,542,000 | 275,727,000 | 314,053,000 | 341,487,000 | 357,853,000 | 382,804,000 | 386,142,000 | 495,701,000 | 505,779,000 | 526,959,000 | 263,876,000 | 325,760,000 | 371,305,000 | 335,780,000 | 275,634,000 | 202,347,000 | 166,083,000 | 206,265,000 | 178,766,000 | 208,382,000 | 229,052,000 | 263,282,000 | 282,159,000 | 306,398,000 | ||
| property and equipment | 3,929,000 | 4,256,000 | 4,495,000 | 4,795,000 | 5,068,000 | 5,288,000 | 5,585,000 | 5,630,000 | 5,876,000 | 6,015,000 | 6,288,000 | 6,660,000 | 6,964,000 | 7,229,000 | 7,575,000 | 7,912,000 | 8,105,000 | 8,501,000 | 8,929,000 | 9,324,000 | 11,190,000 | 12,164,000 | 12,429,000 | 11,381,000 | 6,665,000 | 19,017,000 | 17,270,000 | 16,161,000 | 16,335,000 | 16,844,000 | 17,175,000 | 17,854,000 | 18,633,000 | 18,842,000 | 17,939,000 | 19,446,000 | 23,183,000 | 25,017,000 | 27,477,000 | 33,560,000 | 35,524,000 | 35,013,000 | 36,100,000 | 36,470,000 | 34,859,000 | 35,140,000 | 32,875,000 | 33,484,000 | 35,074,000 | 33,286,000 | 29,117,000 | 23,540,000 | ||
| operating lease right-of-use assets | 10,201,000 | 10,619,000 | 11,028,000 | 11,430,000 | 11,823,000 | 12,208,000 | 12,586,000 | 12,956,000 | 13,319,000 | 13,674,000 | 14,023,000 | 14,365,000 | 14,700,000 | 15,028,000 | 15,350,000 | 15,666,000 | 15,975,000 | 16,279,000 | 16,576,000 | 16,868,000 | 17,156,000 | 17,447,000 | 17,743,000 | 19,793,000 | 25,569,000 | 84,833,000 | ||||||||||||||||||||||||||||
| intangible assets | 2,453,000 | 2,658,000 | 2,860,000 | 3,067,000 | 3,273,000 | 3,478,000 | 3,682,000 | 3,889,000 | 4,096,000 | 152,953,000 | 156,429,000 | 163,381,000 | 165,278,000 | 165,699,000 | 182,722,000 | 185,935,000 | ||||||||||||||||||||||||||||||||||||||
| deferred tax assets | 129,459,000 | 143,563,000 | 144,234,000 | 185,338,000 | 193,019,000 | 206,273,000 | 212,324,000 | 243,645,000 | 257,900,000 | 267,909,000 | 283,661,000 | 304,538,000 | 320,554,000 | 335,440,000 | 333,294,000 | 335,227,000 | 337,800,000 | |||||||||||||||||||||||||||||||||||||
| other assets | 5,151,000 | 5,538,000 | 5,923,000 | 6,285,000 | 4,257,000 | 3,398,000 | 3,608,000 | 3,823,000 | 3,920,000 | 820,000 | 847,000 | 863,000 | 872,000 | 955,000 | 1,000,000 | 855,000 | 879,000 | 924,000 | 943,000 | 881,000 | 820,000 | 838,000 | 5,000 | 20,000 | 26,000 | 56,000 | 114,000 | 708,000 | 771,000 | 809,000 | 799,000 | 738,000 | 783,000 | 1,412,000 | 1,818,000 | 2,243,000 | 3,223,000 | 3,504,000 | 6,028,000 | 3,597,000 | 3,895,000 | 5,091,000 | 5,212,000 | 54,000 | 74,000 | 124,000 | 192,000 | 214,000 | 251,000 | 317,000 | 298,000 | 30,000 | ||
| total assets | 342,946,000 | 327,213,000 | 350,908,000 | 389,519,000 | 395,620,000 | 438,819,000 | 471,073,000 | 524,063,000 | 603,220,000 | 1,155,277,000 | 1,100,519,000 | 1,040,344,000 | 975,690,000 | 1,083,381,000 | 1,126,927,000 | 1,079,371,000 | 1,007,218,000 | 599,344,000 | 559,238,000 | 492,324,000 | 443,538,000 | 404,005,000 | 402,748,000 | 334,343,000 | 315,721,000 | 363,538,000 | 332,050,000 | 416,652,000 | 618,218,000 | 571,095,000 | 605,674,000 | 625,086,000 | 705,079,000 | 701,319,000 | 709,821,000 | 731,978,000 | 700,208,000 | 603,325,000 | 613,426,000 | 653,941,000 | 305,528,000 | 371,064,000 | 418,871,000 | 384,031,000 | 325,093,000 | 246,518,000 | 208,663,000 | 249,176,000 | 219,480,000 | 249,727,000 | 272,024,000 | 304,532,000 | 322,084,000 | 338,130,000 |
| liabilities and stockholders' deficit | ||||||||||||||||||||||||||||||||||||||||||||||||||||||
| current liabilities: | ||||||||||||||||||||||||||||||||||||||||||||||||||||||
| accounts payable | 1,389,000 | 5,827,000 | 2,127,000 | 3,236,000 | 3,227,000 | 6,222,000 | 7,830,000 | 4,698,000 | 3,505,000 | 118,000 | 483,000 | 795,000 | 317,000 | 532,000 | 935,000 | 414,000 | 466,000 | 842,000 | 661,000 | 1,972,000 | 2,104,000 | 2,781,000 | 3,978,000 | 4,505,000 | 7,872,000 | 11,203,000 | 18,123,000 | 3,393,000 | 4,844,000 | 6,569,000 | 3,303,000 | 2,652,000 | 6,921,000 | 1,996,000 | 2,390,000 | 6,507,000 | 2,918,000 | 5,857,000 | 5,202,000 | 5,116,000 | ||||||||||||||
| accrued research and development costs | 4,551,000 | 5,627,000 | 6,681,000 | 9,408,000 | 6,720,000 | 11,880,000 | 21,331,000 | 10,735,000 | 20,122,000 | 2,874,000 | 5,258,000 | 5,673,000 | 6,338,000 | 5,442,000 | 15,896,000 | 1,675,000 | 1,638,000 | 1,254,000 | 1,898,000 | 2,657,000 | 2,400,000 | 2,286,000 | 2,956,000 | 4,956,000 | 6,270,000 | 9,734,000 | 8,219,000 | 5,088,000 | 5,378,000 | 4,673,000 | 7,872,000 | 7,454,000 | 5,106,000 | 8,042,000 | 6,653,000 | 6,625,000 | 2,635,000 | 5,530,000 | 9,270,000 | 2,235,000 | 1,763,000 | 4,946,000 | 6,184,000 | 6,154,000 | 6,907,000 | 7,958,000 | 7,629,000 | 5,429,000 | 8,052,000 | 5,328,000 | 8,573,000 | 8,426,000 | ||
| accrued expenses and other current liabilities | 24,033,000 | 33,439,000 | 26,849,000 | 33,566,000 | 32,406,000 | 31,398,000 | 44,254,000 | 62,714,000 | 79,585,000 | 17,771,000 | 16,700,000 | 17,598,000 | 13,425,000 | 16,852,000 | 23,566,000 | 20,127,000 | 16,253,000 | 18,363,000 | 26,486,000 | 23,885,000 | 17,955,000 | 18,719,000 | 30,465,000 | 30,529,000 | 33,982,000 | 39,591,000 | 45,252,000 | 44,958,000 | 37,829,000 | 30,145,000 | 33,798,000 | 30,817,000 | 31,818,000 | 29,055,000 | 20,598,000 | 19,065,000 | 24,578,000 | |||||||||||||||||
| current portion of operating lease liabilities | 3,220,000 | 3,204,000 | 3,189,000 | 3,173,000 | 3,157,000 | 3,142,000 | 3,126,000 | 3,111,000 | 3,095,000 | 3,080,000 | 3,065,000 | 3,050,000 | 3,066,000 | 3,097,000 | 3,127,000 | 3,157,000 | 3,161,000 | 3,144,000 | 3,128,000 | 3,112,000 | 2,610,000 | 1,876,000 | 1,146,000 | 9,934,000 | 11,904,000 | 12,080,000 | ||||||||||||||||||||||||||||
| current portion of convertible senior notes | 199,332,000 | 199,800,000 | 199,560,000 | 199,321,000 | 199,083,000 | 120,581,000 | 116,858,000 | 114,832,000 | 112,852,000 | |||||||||||||||||||||||||||||||||||||||||||||
| total current liabilities | 232,525,000 | 48,097,000 | 38,846,000 | 49,383,000 | 45,510,000 | 252,442,000 | 276,101,000 | 280,579,000 | 305,390,000 | 23,843,000 | 25,525,000 | 27,117,000 | 23,298,000 | 147,403,000 | 161,698,000 | 145,694,000 | 134,370,000 | 23,603,000 | 32,173,000 | 32,901,000 | 26,695,000 | 27,595,000 | 40,929,000 | 52,795,000 | 110,861,000 | 118,569,000 | 119,524,000 | 112,582,000 | 94,984,000 | 62,336,000 | 64,489,000 | 79,973,000 | 78,893,000 | 95,305,000 | 90,999,000 | 78,113,000 | 67,780,000 | 62,099,000 | 59,813,000 | 41,626,000 | 38,500,000 | 43,966,000 | 62,682,000 | 35,577,000 | 49,121,000 | 52,283,000 | 70,848,000 | 70,844,000 | 60,532,000 | 55,849,000 | 57,201,000 | 54,984,000 | ||
| operating lease obligations, net of current portion | 11,117,000 | 11,717,000 | 12,304,000 | 12,882,000 | 13,452,000 | 14,004,000 | 14,543,000 | 15,074,000 | 15,598,000 | 16,105,000 | 16,599,000 | 17,087,000 | 17,567,000 | 18,031,000 | 18,484,000 | 18,930,000 | 19,394,000 | 19,862,000 | 20,318,000 | 20,767,000 | 21,211,000 | 21,646,000 | 22,082,000 | |||||||||||||||||||||||||||||||
| convertible senior notes, net of current portion | 199,160,000 | 198,988,000 | 198,817,000 | 198,647,000 | 198,477,000 | 198,309,000 | 198,141,000 | 197,974,000 | 396,653,000 | 396,251,000 | 395,850,000 | 395,451,000 | 395,053,000 | 337,333,000 | 333,212,000 | 329,155,000 | ||||||||||||||||||||||||||||||||||||||
| revolving credit facility | 385,000,000 | 385,000,000 | 385,000,000 | 400,000,000 | 425,000,000 | 275,000,000 | 300,000,000 | 325,000,000 | 400,000,000 | |||||||||||||||||||||||||||||||||||||||||||||
| other liabilities | 22,466,000 | 17,292,000 | 17,105,000 | 39,771,000 | 34,738,000 | 29,414,000 | 28,415,000 | 30,948,000 | 31,035,000 | 11,824,000 | 9,766,000 | 9,227,000 | 6,491,000 | 5,111,000 | 3,501,000 | 1,594,000 | 1,482,000 | 1,630,000 | 1,763,000 | 518,000 | 602,000 | 705,000 | 734,000 | 492,000 | 2,626,000 | 2,723,000 | 2,530,000 | 2,530,000 | 5,060,000 | 5,060,000 | 8,190,000 | 8,190,000 | 8,190,000 | 10,120,000 | 10,120,000 | 10,120,000 | 10,645,000 | 3,845,000 | 1,653,000 | 909,000 | 703,000 | |||||||||||||
| commitments and contingencies | ||||||||||||||||||||||||||||||||||||||||||||||||||||||
| stockholders’ deficit: | ||||||||||||||||||||||||||||||||||||||||||||||||||||||
| preferred stock, 0.001 par value, 75,000,000 shares authorized, no shares issued and outstanding | ||||||||||||||||||||||||||||||||||||||||||||||||||||||
| class a common stock | 162,000 | 162,000 | 160,000 | 160,000 | 160,000 | 159,000 | 156,000 | 156,000 | 156,000 | 155,000 | 154,000 | 153,000 | 153,000 | 155,000 | 162,000 | 163,000 | 163,000 | 162,000 | 161,000 | 160,000 | 160,000 | 159,000 | 158,000 | 157,000 | 156,000 | 156,000 | 154,000 | 140,000 | 139,000 | 138,000 | 135,000 | 135,000 | 134,000 | 131,000 | 130,000 | 128,000 | 127,000 | 126,000 | 126,000 | 120,000 | 119,000 | 96,000 | 82,000 | 77,000 | 76,000 | 75,000 | 59,000 | 51,000 | 49,000 | 44,000 | 19,000 | 19,000 | ||
| additional paid-in capital | 1,405,224,000 | 1,400,612,000 | 1,395,317,000 | 1,390,549,000 | 1,382,220,000 | 1,373,022,000 | 1,355,195,000 | 1,374,908,000 | 1,366,989,000 | 1,357,359,000 | 1,348,600,000 | 1,336,153,000 | 1,328,290,000 | 1,350,268,000 | 1,543,357,000 | 1,558,760,000 | 1,546,420,000 | 1,536,160,000 | 1,528,535,000 | 1,515,004,000 | 1,506,671,000 | 1,497,171,000 | 1,478,823,000 | 1,466,886,000 | 1,421,215,000 | 1,413,077,000 | 1,394,603,000 | 1,378,195,000 | 1,357,224,000 | 1,333,791,000 | 1,303,123,000 | 1,293,292,000 | 1,273,853,000 | 1,237,569,000 | 1,226,311,000 | 1,214,174,000 | 1,196,345,000 | 1,188,807,000 | 1,068,685,000 | 1,029,501,000 | 1,016,271,000 | 803,363,000 | 657,320,000 | 643,154,000 | 637,478,000 | 632,029,000 | 538,241,000 | 534,749,000 | 530,374,000 | 523,809,000 | 518,217,000 | 516,403,000 | ||
| accumulated deficit | -1,711,522,000 | -1,735,121,000 | -1,697,735,000 | -1,699,991,000 | -1,703,637,000 | -1,702,777,000 | -1,698,615,000 | -1,697,528,000 | -1,712,849,000 | -650,662,000 | -696,376,000 | -745,243,000 | -795,560,000 | -832,640,000 | -937,608,000 | -978,982,000 | -1,034,827,000 | -1,426,130,000 | -1,466,056,000 | -1,509,260,000 | -1,543,683,000 | -1,568,887,000 | -1,572,232,000 | -1,620,090,000 | -1,640,738,000 | -1,650,412,000 | -1,591,128,000 | -1,575,635,000 | -1,401,284,000 | -1,351,904,000 | -1,320,845,000 | -1,288,548,000 | -1,244,324,000 | -1,178,318,000 | ||||||||||||||||||||
| accumulated other comprehensive income | -2,026,000 | 294,000 | -752,000 | 61,000 | 39,000 | 29,000 | 48,000 | 22,000 | 3,000 | 3,000 | 12,000 | 7,000 | 3,000 | 6,000 | 53,000 | 52,000 | 48,000 | 44,000 | ||||||||||||||||||||||||||||||||||||
| total stockholders’ deficit | -308,162,000 | -334,053,000 | -301,335,000 | -311,334,000 | -321,727,000 | -330,518,000 | -36,852,000 | -71,557,000 | -93,251,000 | -153,047,000 | -219,367,000 | -237,179,000 | ||||||||||||||||||||||||||||||||||||||||||
| total liabilities and stockholders’ deficit | 342,946,000 | 327,213,000 | 350,908,000 | 389,519,000 | 395,620,000 | 438,819,000 | 443,538,000 | 404,005,000 | 402,748,000 | 334,343,000 | 315,721,000 | 363,538,000 | ||||||||||||||||||||||||||||||||||||||||||
| accumulated other comprehensive loss | 923,000 | -2,052,000 | -470,000 | -922,000 | -3,031,000 | -44,000 | -91,000 | -24,000 | -41,000 | |||||||||||||||||||||||||||||||||||||||||||||
| liabilities and stockholders' equity | ||||||||||||||||||||||||||||||||||||||||||||||||||||||
| stockholders’ equity | ||||||||||||||||||||||||||||||||||||||||||||||||||||||
| restricted cash | 788,000 | 788,000 | 1,250,000 | 1,250,000 | 1,250,000 | 1,250,000 | 1,250,000 | 1,250,000 | 1,250,000 | 1,735,000 | 1,735,000 | 1,735,000 | 1,735,000 | 1,250,000 | 1,250,000 | 1,250,000 | 7,676,000 | 7,676,000 | 1,250,000 | 1,250,000 | 7,676,000 | 8,306,000 | 7,056,000 | 7,057,000 | 7,057,000 | 1,190,000 | 8,247,000 | 8,247,000 | 8,747,000 | 8,147,000 | 8,147,000 | 8,147,000 | 8,147,000 | 8,147,000 | 8,147,000 | 7,647,000 | 7,647,000 | 7,647,000 | 2,833,000 | 10,510,000 | 8,162,000 | |||||||||||||
| restricted cash, net of current portion | 510,000 | 510,000 | 485,000 | 485,000 | 485,000 | 485,000 | 485,000 | 485,000 | 485,000 | 485,000 | 485,000 | 485,000 | 485,000 | 971,000 | 971,000 | 971,000 | 971,000 | 971,000 | 6,426,000 | 6,426,000 | 7,057,000 | 8,247,000 | ||||||||||||||||||||||||||||||||
| accounts receivable, net of current portion | 14,589,000 | 14,439,000 | 14,289,000 | 14,143,000 | 23,998,000 | 23,852,000 | 23,706,000 | 23,563,000 | 23,401,000 | 23,197,000 | 22,995,000 | 22,795,000 | 32,597,000 | 32,398,000 | ||||||||||||||||||||||||||||||||||||||||
| note hedge warrants | 19,000 | 1,000 | 152,000 | 899,000 | 1,316,000 | 5,489,000 | 11,061,000 | 7,979,000 | 12,088,000 | 7,695,000 | 12,958,000 | 12,207,000 | 24,260,000 | 8,768,000 | 50,191,000 | 39,388,000 | 33,763,000 | 122,778,000 | 143,019,000 | 96,129,000 | 103,743,000 | 149,458,000 | 133,424,000 | 120,121,000 | 86,838,000 | 68,193,000 | 62,976,000 | 69,456,000 | ||||||||||||||||||||||||||
| total stockholders’ equity | -346,295,000 | -325,679,000 | -346,777,000 | 706,852,000 | 652,378,000 | 591,063,000 | 532,883,000 | 517,783,000 | 605,911,000 | 579,941,000 | 511,756,000 | 110,192,000 | 62,640,000 | 5,904,000 | 9,848,000 | 4,870,000 | 29,637,000 | 66,716,000 | 59,458,000 | 81,381,000 | 90,935,000 | 100,458,000 | 140,283,000 | 68,162,000 | 141,831,000 | 188,943,000 | 139,416,000 | 58,523,000 | 182,108,000 | 128,781,000 | 164,146,000 | 112,930,000 | 130,117,000 | 144,585,000 | 168,067,000 | 173,550,000 | 188,802,000 | |||||||||||||||||
| total liabilities and stockholders’ equity | 471,073,000 | 524,063,000 | 603,220,000 | 1,155,277,000 | 1,100,519,000 | 1,040,344,000 | 975,690,000 | 1,083,381,000 | 1,126,927,000 | 1,079,371,000 | 1,007,218,000 | 599,344,000 | 559,238,000 | 492,324,000 | 705,079,000 | 701,319,000 | 731,978,000 | 700,208,000 | 603,325,000 | 613,426,000 | 653,941,000 | 305,528,000 | 371,064,000 | 418,871,000 | 384,031,000 | 325,093,000 | 246,518,000 | 208,663,000 | 249,176,000 | 219,480,000 | 249,727,000 | 272,024,000 | 304,532,000 | 322,084,000 | 338,130,000 | |||||||||||||||||||
| ironwood pharmaceuticals, inc. stockholders’ equity: | ||||||||||||||||||||||||||||||||||||||||||||||||||||||
| total ironwood pharmaceuticals, inc. stockholders’ equity | -323,216,000 | -345,704,000 | 168,067,000 | 170,740,000 | 185,919,000 | |||||||||||||||||||||||||||||||||||||||||||||||||
| noncontrolling interests | -2,463,000 | -1,073,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||
| stockholders’ equity: | ||||||||||||||||||||||||||||||||||||||||||||||||||||||
| convertible note hedges | 1,428,000 | 1,115,000 | 7,854,000 | 11,262,000 | 11,346,000 | 13,065,000 | 8,252,000 | 16,131,000 | 15,847,000 | 31,366,000 | 11,357,000 | 60,720,000 | 50,589,000 | 41,020,000 | 142,774,000 | 159,526,000 | 113,445,000 | 121,836,000 | 171,880,000 | 150,509,000 | 137,302,000 | 99,478,000 | 77,688,000 | 72,494,000 | 90,314,000 | |||||||||||||||||||||||||||||
| convertible senior notes | 436,078,000 | 430,256,000 | 424,539,000 | 418,924,000 | 413,409,000 | 407,994,000 | 402,675,000 | 274,395,000 | 269,947,000 | 265,601,000 | 261,355,000 | 257,206,000 | 253,153,000 | 245,324,000 | 241,544,000 | 237,851,000 | 230,717,000 | 227,273,000 | 223,908,000 | 217,408,000 | 214,292,000 | |||||||||||||||||||||||||||||||||
| related party accounts receivable | 73,404,000 | 105,967,000 | 94,553,000 | 81,182,000 | 69,326,000 | 59,959,000 | 55,182,000 | 73,771,000 | 65,663,000 | 75,803,000 | 56,382,000 | 49,995,000 | 52,541,000 | 51,875,000 | 52,110,000 | 34,401,000 | 25,992,000 | 32,987,000 | 4,455,000 | 10,324,000 | 5,298,000 | 36,000 | 13,000 | 2,444,000 | 667,000 | 2,517,000 | 3,977,000 | 4,677,000 | 6,156,000 | 4,531,000 | ||||||||||||||||||||||||
| inventory | 648,000 | 2,298,000 | 1,735,000 | 593,000 | 76,000 | 1,099,000 | 1,705,000 | 479,000 | 1,513,000 | 4,950,000 | 12,989,000 | 23,413,000 | 20,379,000 | 19,704,000 | 965,000 | |||||||||||||||||||||||||||||||||||||||
| related party accounts payable | 400,000 | 751,000 | 1,058,000 | 1,509,000 | 1,593,000 | 2,036,000 | 5,000 | 18,000 | 7,268,000 | 26,441,000 | 2,141,000 | 3,705,000 | 1,175,000 | |||||||||||||||||||||||||||||||||||||||||
| deferred revenue | 875,000 | 875,000 | 875,000 | 875,000 | 1,278,000 | 13,521,000 | 225,000 | 741,000 | ||||||||||||||||||||||||||||||||||||||||||||||
| current assets of discontinued operations | ||||||||||||||||||||||||||||||||||||||||||||||||||||||
| goodwill | 785,000 | 785,000 | 785,000 | 785,000 | 785,000 | 785,000 | 785,000 | 785,000 | 785,000 | 785,000 | 785,000 | 649,000 | 649,000 | |||||||||||||||||||||||||||||||||||||||||
| non-current assets of discontinued operations | ||||||||||||||||||||||||||||||||||||||||||||||||||||||
| capital lease obligations | 73,000 | 171,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||
| current portion of deferred rent | 252,000 | 247,000 | 242,000 | 237,000 | 195,000 | 205,000 | 588,000 | 7,821,000 | 7,923,000 | 7,684,000 | 5,026,000 | 5,009,000 | 5,006,000 | 2,817,000 | 2,803,000 | 2,762,000 | 2,749,000 | 4,531,000 | 4,517,000 | 4,350,000 | 3,707,000 | 3,282,000 | 2,877,000 | 2,374,000 | 1,150,000 | 196,000 | ||||||||||||||||||||||||||||
| current portion of 2026 notes | 48,797,000 | 45,961,000 | 47,554,000 | 39,191,000 | 24,861,000 | 11,958,000 | ||||||||||||||||||||||||||||||||||||||||||||||||
| current portion of contingent consideration | 51,000 | 74,000 | 423,000 | 355,000 | 699,000 | 14,985,000 | 14,561,000 | 14,578,000 | 597,000 | |||||||||||||||||||||||||||||||||||||||||||||
| current liabilities of discontinued operations | ||||||||||||||||||||||||||||||||||||||||||||||||||||||
| capital lease obligations, net of current portion | 158,000 | 21,000 | 141,000 | 198,000 | 253,000 | 1,068,000 | 1,959,000 | 2,268,000 | 3,158,000 | 2,842,000 | 198,000 | 254,000 | 361,000 | 364,000 | 435,000 | 481,000 | 540,000 | 598,000 | 429,000 | 427,000 | 74,000 | |||||||||||||||||||||||||||||||||
| deferred rent, net of current portion | 6,308,000 | 6,113,000 | 6,058,000 | 5,860,000 | 4,484,000 | 3,515,000 | 2,554,000 | 2,490,000 | 4,409,000 | 7,131,000 | 7,714,000 | 8,821,000 | 9,935,000 | 7,431,000 | 8,127,000 | 10,218,000 | 10,907,000 | 9,690,000 | 10,832,000 | 11,964,000 | 13,308,000 | 14,379,000 | 13,939,000 | 15,772,000 | 16,330,000 | 10,703,000 | ||||||||||||||||||||||||||||
| 2026 notes, net of current portion | 78,330,000 | 90,140,000 | 100,537,000 | 108,589,000 | 122,614,000 | 135,220,000 | ||||||||||||||||||||||||||||||||||||||||||||||||
| operating lease liabilities, net of current portion | 22,660,000 | 18,685,000 | 79,950,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||
| revenues: | ||||||||||||||||||||||||||||||||||||||||||||||||||||||
| collaborative arrangements revenue | 66,152,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||
| product revenue | ||||||||||||||||||||||||||||||||||||||||||||||||||||||
| sale of active pharmaceutical ingredient | 2,578,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||
| total revenues | 68,730,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||
| cost and expenses: | ||||||||||||||||||||||||||||||||||||||||||||||||||||||
| cost of revenues, excluding amortization of acquired intangible assets | 1,043,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||
| research and development | 53,990,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||
| selling, general and administrative | 64,741,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||
| amortization of acquired intangible assets | ||||||||||||||||||||||||||||||||||||||||||||||||||||||
| loss on fair value remeasurement of contingent consideration | ||||||||||||||||||||||||||||||||||||||||||||||||||||||
| restructuring expenses | 3,328,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||
| total cost and expenses | 123,102,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||
| income from operations | -54,372,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||
| other income: | ||||||||||||||||||||||||||||||||||||||||||||||||||||||
| interest expense | -9,592,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||
| interest and investment income | 736,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||
| gain on derivatives | 3,944,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||
| other income | -4,912,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||
| net income | -59,284,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||
| net income per share | -380 | |||||||||||||||||||||||||||||||||||||||||||||||||||||
| weighted-average number of common shares used in net income per share—basic and diluted: | 154,956,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||
| available-for-sale securities | 19,836,000 | 35,831,000 | 49,659,000 | 62,777,000 | 90,763,000 | 162,020,000 | 136,936,000 | 48,041,000 | 153,526,000 | 214,229,000 | 236,865,000 | 152,173,000 | 206,621,000 | 127,140,000 | 81,077,000 | 136,727,000 | 67,456,000 | 70,570,000 | 70,496,000 | 106,309,000 | 152,912,000 | 174,355,000 | 192,135,000 | 236,221,000 | 222,230,000 | |||||||||||||||||||||||||||||
| liabilities and stockholders' (deficit) equity | ||||||||||||||||||||||||||||||||||||||||||||||||||||||
| contingent consideration, net of current portion | 33,228,000 | 31,389,000 | 69,830,000 | 71,213,000 | 64,712,000 | 81,682,000 | 87,052,000 | |||||||||||||||||||||||||||||||||||||||||||||||
| stockholders’ (deficit) equity: | ||||||||||||||||||||||||||||||||||||||||||||||||||||||
| class b common stock | 14,000 | 14,000 | 14,000 | 14,000 | 15,000 | 15,000 | 15,000 | 15,000 | 16,000 | 16,000 | 16,000 | 16,000 | 18,000 | 19,000 | 25,000 | 27,000 | 31,000 | 32,000 | 32,000 | 42,000 | 49,000 | 51,000 | 55,000 | 79,000 | 79,000 | |||||||||||||||||||||||||||||
| total stockholders’ (deficit) equity | -196,371,000 | -197,295,000 | -43,951,000 | -18,052,000 | -17,579,000 | |||||||||||||||||||||||||||||||||||||||||||||||||
| total liabilities and stockholders’ (deficit) equity | 332,050,000 | 416,652,000 | 618,218,000 | 571,095,000 | 625,086,000 | |||||||||||||||||||||||||||||||||||||||||||||||||
| accounts payable and related party accounts payable | 9,332,000 | 23,786,000 | 11,609,000 | 17,514,000 | 21,190,000 | 20,578,000 | 19,752,000 | 8,999,000 | 4,741,000 | 5,904,000 | 6,650,000 | 5,227,000 | ||||||||||||||||||||||||||||||||||||||||||
| current portion of capital lease obligations | 2,465,000 | 3,359,000 | 4,411,000 | 5,097,000 | 5,501,000 | 3,525,000 | 2,451,000 | 2,447,000 | 2,325,000 | 1,203,000 | 1,177,000 | 1,104,000 | 1,156,000 | 223,000 | 242,000 | 280,000 | 277,000 | 271,000 | 228,000 | 229,000 | 241,000 | 227,000 | 246,000 | 147,000 | ||||||||||||||||||||||||||||||
| consolidated balance sheet data: | ||||||||||||||||||||||||||||||||||||||||||||||||||||||
| cash, cash equivalents and available-for-sale securities | 221,416,000 | 305,216,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||
| working capital | 245,569,000 | 289,050,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||
| deferred revenue, including current portion | ||||||||||||||||||||||||||||||||||||||||||||||||||||||
| debt financing and convertible notes, including current portion | 396,091,000 | 366,492,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||
| capital lease obligations, including current portion | 4,077,000 | 6,309,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||
| total liabilities | 595,826,000 | 643,105,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||
| pharma notes payable | ||||||||||||||||||||||||||||||||||||||||||||||||||||||
| 2026 notes | 146,605,000 | 146,316,000 | 146,037,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||
| current portion of deferred revenue | 4,127,000 | 8,519,000 | 9,309,000 | 7,191,000 | 7,191,000 | 7,191,000 | 6,447,000 | 6,128,000 | 5,074,000 | 3,299,000 | 3,130,000 | 13,578,000 | 24,935,000 | 47,647,000 | 48,555,000 | 40,050,000 | 35,490,000 | 35,490,000 | 35,607,000 | |||||||||||||||||||||||||||||||||||
| current portion of pharma notes payable | 8,405,000 | 35,259,000 | 28,242,000 | 20,121,000 | 17,571,000 | |||||||||||||||||||||||||||||||||||||||||||||||||
| deferred revenue, net of current portion | 3,596,000 | 5,393,000 | 7,191,000 | 8,879,000 | 10,147,000 | 13,952,000 | 17,217,000 | 18,782,000 | 19,565,000 | 20,348,000 | 21,913,000 | 33,144,000 | 52,370,000 | 64,415,000 | 73,288,000 | 82,038,000 | ||||||||||||||||||||||||||||||||||||||
| pharma notes payable, net of current portion | 131,944,000 | 111,938,000 | 124,672,000 | 141,781,000 | 147,793,000 | |||||||||||||||||||||||||||||||||||||||||||||||||
| liabilities and stockholders’ equity | ||||||||||||||||||||||||||||||||||||||||||||||||||||||
| restricted cash, current portion | 500,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||
| accrued expenses | 18,945,000 | 18,735,000 | 19,048,000 | 17,407,000 | 17,124,000 | 20,464,000 | 16,689,000 | 13,216,000 | 11,598,000 | 9,247,000 | 6,648,000 | 6,394,000 | 6,573,000 | 5,523,000 | 4,326,000 | |||||||||||||||||||||||||||||||||||||||
| current portion of notes payable | 13,207,000 | 6,577,000 | 4,381,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||
| notes payable, net of current portion | 158,159,000 | 168,139,000 | 170,312,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||
| notes payable | 174,628,000 | 174,601,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||
| preferred stock, 0.001 par value, 75,000,000 shares authorized, no shares issued and outstanding at june 30, 2013 and december 31, 2012 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||
| preferred stock, 0.001 par value, 75,000,000 shares authorized, no shares issued and outstanding at march 31, 2013 and december 31, 2012 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||
| preferred stock, 0.001 par value, 75,000,000 shares authorized, no shares issued and outstanding at september 30, 2012 and december 31, 2011 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||
| preferred stock, 0.001 par value, 75,000,000 shares authorized, no shares issued and outstanding at june 30, 2012 and december 31, 2011 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||
| preferred stock, 0.001 par value, 75,000,000 shares authorized, no shares issued and outstanding at march 31, 2012 and december 31, 2011 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||
| prepaid expenses and other assets | 2,896,000 | 4,658,000 | 4,299,000 | 4,569,000 | 4,202,000 | 3,107,000 | ||||||||||||||||||||||||||||||||||||||||||||||||
| other current liabilities | 194,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||
| long-term restricted cash | 7,647,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||
| long-term assets of discontinued operations | ||||||||||||||||||||||||||||||||||||||||||||||||||||||
| current portion of long-term debt | 1,017,000 | 1,166,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||
| long-term debt, net of current portion | 1,288,000 | 1,529,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||
| long-term liabilities of discontinued operations | ||||||||||||||||||||||||||||||||||||||||||||||||||||||
| convertible preferred stock, 0.001 par value, no shares authorized at september 30, 2010 and 74,942,226 shares authorized at december 31, 2009, no shares issued and outstanding at september 30, 2010 and 69,904,843 shares issued and outstanding at december 31, 2009 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||
| preferred stock, 0.001 par value, 75,000,000 shares authorized, no shares issued and outstanding at september 30, 2010, and no shares authorized, issued or outstanding at december 31, 2009 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||
| noncontrolling interest | 2,810,000 | 2,883,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||
| convertible preferred stock, 0.001 par value, no shares authorized at june 30, 2010 and 74,942,226 shares authorized at december 31, 2009, no shares issued and outstanding at june 30, 2010 and 69,904,843 shares issued and outstanding at december 31, 2009 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||
| preferred stock, 0.001 par value, 75,000,000 shares authorized, no shares issued and outstanding at june 30, 2010 and no shares authorized, issued or outstanding at december 31, 2009 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||
| convertible preferred stock, 0.001 par value, no shares authorized at march 31, 2010 and 74,942,226 shares authorized at december 31, 2009, no shares issued and outstanding at march 31, 2010 and 69,904,843 shares issued and outstanding at december 31, 2009 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||
| preferred stock, 0.001 par value, 75,000,000 shares authorized, no shares issued and outstanding at march 31, 2010 and no shares authorized at december 31, 2009 |
We provide you with 20 years of balance sheets for Ironwood Pharmaceuticals stock, allowing you to gain comprehensive visibility into the fundamentals of the company. Our detailed breakdowns include key financial metrics such as asset and liabilities, payables and receivables, long debts and short debts, cash and inventories, expenses and profits. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of Ironwood Pharmaceuticals. Explore the full financial landscape of Ironwood Pharmaceuticals stock with our expertly curated balance sheets.
The information provided in this report about Ironwood Pharmaceuticals stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.